VIEW
IN BROWSER
EDITOR'S
NOTE: Big4Bio newsletters will not be
published on Nov 26th-28th; they will resume
distribution on Monday, Dec 1st.
|
 |
|
November 25, 2025 |
| Covering
Life Sciences Drugs, Diagnostics,
Devices, Digital Health |
|
|
|
* may need subscription to view |
- Alzheimer's Drug Discovery Foundation:
Readout of Phase 3 Semaglutide Trials Marks
Critical Moment in Alzheimer’s Research and
Suggests Potential for Combination Therapies More
- Bristol Myers Squibb: Receives
Approval From the European Commission to
Expand Use of CAR T Cell Therapy Breyanzi
for Relapsed or Refractory Mantle Cell
Lymphoma
More
More*
- Made Scientific and Cellergy
Therapeutics: Manufacturing Partnership to
Advance First-in-Human Mitochondrial Therapy
More
- Otsuka Pharmaceutical: Submits New Drug
Application to U.S. FDA for Centanafadine for
the Treatment of ADHD in Children,
Adolescents, and Adults More
- Regeneron and Sanofi: Dupixent
(dupilumab) Approved as the First Targeted
Medicine in the European Union (EU) in Over
a Decade for Chronic Spontaneous Urticaria
(CSU) More
|
|
- Get
Full Access to BYTE51 Life Sciences
Intelligence for 50% Off
More
- JPM Week Conference Readiness
Packages (Big4Bio Subscriber Discount) More
- Mesoblast: Trading Update at Annual General
Meeting Highlights Continued Strong Growth in
Ryoncil Revenue More
- Pathway to Cures: Invests in SeraGene
Therapeutics
More
|
|
- More on FDA Nod for Padcev Plus Keytruda for
Certain Bladder Cancer Patients More*
More*
- Subscribe to LifeSci Startup for
Updates on US Startups More
- The Big4Bio Podcast: Every Moment
Matters: How NAMs Are Rewriting the Rules of
Antibody Discovery
Podcast
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: NYC Life Science Company
Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
Feature your company |
|
Apply to have your company
showcased by Big4Bio. |
|
|
|
|
|
 |
| M&A
in Life Sciences: The Turning Tide
– Why Now is a Strategic
Inflection for Biopharma and
Biotech |
|
Learn More
→ |
|
|
- Hiring Outlook: Job Openings Will Likely
Drop as 2025 Winds Down But Could Rise in 2026
More
- ICYMI: CEO's Perspective: Big Moves Come
with Big Responsibilities More
- ICYMI: CEO's Perspective: The High Cost of
Job Hopping More
- ICYMI: Elevating Executive Presence: A
Blueprint for Life Sciences and Biotech
Leaders More
- ICYMI: The Power of Peer Learning: Why Even
Top Biotech Leaders Need Mentorship More
- ICYMI: What’s Next in Precision Medicine:
Leadership Challenges and Opportunities More
- Jeff Bluestone, Stephen Dilly Talk CEO
Handoff, What’s Next for Sonoma; Scott
Gottlieb’s Next Move More*
|
|
 |
Event
Center
|
Note:
Events may be in any Big4Bio region or
virtual |
|
- Compounding
Pharmacy Compliance (Save 10% with VIP code:
25B4B10) Dec
9-10
- PBM Contracting Summit (Save 10% with VIP
code: 25B4B10) Dec
9-10
- Trade
and Channel Strategies (Save 10% with VIP
code: 25B4B10) Dec
9-11
- The Power of Presenting at Biotech Showcase
Dec 10
- Advancing
Drug Development Forum Dec
11
- Know
Before You Go: AI in 2026 — Signals,
Risks, and Real-World Impact (Pre-JPM
Event) Jan
6
- BLPN
Investor Summit Jan
8-10
|
SEE FULL
EVENT SCHEDULE AT THE BIOCALENDAR
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:NYC,
all rights reserved 2025
© 2025
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
